Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Vanderbilt University has synthesized metabotropic glutamate (mGlu2) receptor negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, autism ...

Neurocrine Biosciences' stock dropped after a lackluster trial. Click here to read more about the potential for this biotech ...

Geneva-based Neurosterix’s lead drug candidate is a selective muscarinic M4 positive allosteric modulator (PAM) with potential as a treatment for schizophrenia, and it will also work on a ...

today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future development in sub Ad ...

allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, today announced its intention to re-domicile from ...

Toxic versus positive. In response to the vein-popping, furious, felon model of the right, the left is offering us a more morally upstanding and expansive “positive masculinity.” ...